The estimated Net Worth of Kathleen Ford is at least $3.97 millió dollars as of 29 January 2024. Ms. Ford owns over 1,496 units of Kura Oncology Inc stock worth over $429,448 and over the last 5 years she sold KURA stock worth over $51,922. In addition, she makes $3,485,030 as Chief Operating Officer at Kura Oncology Inc.
Sign up
Ms. Ford KURA stock SEC Form 4 insiders trading
Kathleen has made over 6 trades of the Kura Oncology Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 1,496 units of KURA stock worth $26,629 on 29 January 2024.
The largest trade she's ever made was exercising 12,500 units of Kura Oncology Inc stock on 14 September 2020 worth over $242,875. On average, Kathleen trades about 3,141 units every 103 days since 2019. As of 29 January 2024 she still owns at least 21,602 units of Kura Oncology Inc stock.
You can see the complete history of Ms. Ford stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kathleen Ford biography
Kathleen Ford serves as Chief Operating Officer of the Company. Prior to joining us, from 2012 to May 2017, she served as Senior Vice President, Head of Global Clinical Operations, at Merck Serono, a division of Merck KGaA, where she led clinical and development operations toward successful drug registrations in both the United States and Europe. From 2002 to 2009, she served in roles of increasing responsibility at Millennium Pharmaceuticals, Inc., a privately-held pharmaceutical company, most recently as Vice President, Clinical Operations, where she led the global operational management of clinical trial activities in all phases of development. From 1993 to 2002, she served as Director of Clinical Operations at Alkermes plc, a publicly-held biopharmaceutical company, where she managed the clinical development for two product approvals. Ms. Ford earned her R.N. from Massachusetts General Hospital School of Nursing and her B.S.N. from Fitchburg State College.
What is the salary of Kathleen Ford?
As the Chief Operating Officer of Kura Oncology Inc, the total compensation of Kathleen Ford at Kura Oncology Inc is $3,485,030. There are no executives at Kura Oncology Inc getting paid more.
How old is Kathleen Ford?
Kathleen Ford is 73, she's been the Chief Operating Officer of Kura Oncology Inc since 2019. There are 1 older and 20 younger executives at Kura Oncology Inc. The oldest executive at Kura Oncology Inc is Kathleen Ford, 74, who is the Chief Operating Officer.
What's Kathleen Ford's mailing address?
Kathleen's mailing address filed with the SEC is C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA, 92130.
Insiders trading at Kura Oncology Inc
Over the last 6 years, insiders at Kura Oncology Inc have traded over $16,903,587 worth of Kura Oncology Inc stock and bought 50,000 units worth $575,000 . The most active insiders traders include Faheem Hasnain, Troy Edward Wilson és Mary T Szela. On average, Kura Oncology Inc executives and independent directors trade stock every 63 days with the average trade being worth of $626,260. The most recent stock trade was executed by Teresa Brophy Bair on 20 May 2024, trading 2,615 units of KURA stock currently worth $57,922.
What does Kura Oncology Inc do?
at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.
What does Kura Oncology Inc's logo look like?
Complete history of Ms. Ford stock trades at Kura Oncology Inc
Kura Oncology Inc executives and stock owners
Kura Oncology Inc executives and other stock owners filed with the SEC include:
-
Kathleen Ford,
Chief Operating Officer -
Troy Wilson,
Chairman of the Board, President, Chief Executive Officer -
Marc Grasso,
Chief Financial Officer and Chief Business Officer -
James Basta,
Chief Legal Officer and Secretary -
Dr. Troy Edward Wilson,
Chairman, CEO & Pres -
Dr. Troy Edward Wilson J.D., Ph.D.,
Chairman, CEO, Pres & Principal Financial Officer -
Dr. Marc Grasso,
CFO & Chief Bus. Officer -
Kathleen Ford,
Chief Operating Officer -
Kirsten Flowers,
Chief Commercial Officer -
Dr. Marc Grasso M.D.,
Advisor -
Dr. Stephen Dale M.D.,
Chief Medical Officer -
Diane Parks,
Independent Director -
Robert Hoffman,
Independent Director -
Faheem Hasnain,
Lead Independent Director -
Thomas Malley,
Independent Director -
Steven Stein,
Independent Director -
Mary Szela,
Independent Director -
Bridget Martell,
Acting Chief Medical Officer -
Kirsten Flowers,
Chief Commercial Officer -
Stephen Dale,
Chief Medical Officer -
Thomas Doyle,
Principal Accounting Officer & Sr. VP of Fin. and Accounting -
Dr. Nic G. Scalfarotto,
Sr. VP of Regulatory Affairs -
Dr. Roger Bakale Ph.D.,
VP and Head of CMC, Clinical & Commercial Manufacturing -
Teresa Brophy Bair Esq., J.D.,
Chief Legal Officer & Corp. Sec. -
James E. Basta J.D., Esq.,
Chief Compliance Officer & Corp. Sec. -
Pete De Spain,
VP of Investor Relations & Corp. Communications -
Teresa Brophy Bair,
Chief Legal Officer -
Antonio Gualberto,
Head of Development & CMO -
Pingda Ren,
SVP Chemistry&Pharma Sciences -
Annette North,
SVP, General Counsel -
Carol Schafer,
-
Helen Louise Collins,
-
Brian T. Powl,
Chief Commercial Officer -
Thomas James Doyle,
SVP, Finance & Accounting